{
  "id": "crc-biomarker-by-method",
  "display_name": "CRC Biomarker Testing by Method",
  "cohort": "CRC Biomarker Testing, by Method (2024–2025)",
  "insight_type": "Precision Medicine Utilization",
  "summary": "CRC testing method variation: IHC for MSI (82%) and single-gene PCR (78%) are common, while comprehensive NGS (35%) and RNA-seq (28%) are underutilized, representing a $230,000 opportunity.",
  "chart": {
    "type": "bar",
    "unit": "method",
    "data": [
      { "name": "IHC (MSI/MMR)", "value": 82, "gap": 12, "highlight": false },
      { "name": "PCR (single-gene)", "value": 78, "gap": 8, "highlight": false },
      { "name": "FISH (HER2)", "value": 52, "gap": -18, "highlight": true },
      { "name": "Liquid Biopsy", "value": 42, "gap": -28, "highlight": true },
      { "name": "NGS Panel", "value": 35, "gap": -35, "highlight": true },
      { "name": "RNA-seq", "value": 28, "gap": -42, "highlight": true }
    ],
    "benchmark": 70,
    "nccn_target": 85
  },
  "financial_impact": {
    "annual_opportunity": "$230,000/year",
    "math": "$230,000/year = 35% testing gap (NGS) × 37 CRC patients × $17,800 improved therapy matching"
  },
  "clinical_impact": {
    "description": "Comprehensive NGS panel testing significantly improves CRC therapy matching and outcomes.",
    "metrics": [
      {
        "type": "PFS",
        "value": "+6.2 months",
        "description": "Improved progression-free survival with NGS-guided therapy"
      },
      {
        "type": "OS",
        "value": "+9.1 months",
        "description": "Overall survival benefit with comprehensive testing"
      },
      {
        "type": "ORR",
        "value": "+38%",
        "description": "Higher objective response rate with matched therapies"
      },
      {
        "type": "CT",
        "value": "+45%",
        "description": "Increased clinical trial eligibility identification"
      },
      {
        "type": "AEs",
        "value": "-32%",
        "description": "Reduced adverse events with optimized treatment selection"
      }
    ],
    "quantitative": "+9.1 months OS"
  },
  "peer_comparison": {
    "description": "Leading colorectal cancer programs utilize NGS panel testing in >75% of cases, vs. your 35%, identifying more actionable alterations.",
    "peer_benchmark": 75,
    "financial_impact": {
      "annual_opportunity": "$285,000/year",
      "math": "$285,000/year = 40% gap to peer benchmark × 40 patients × $17,800 improved care value"
    },
    "action_steps": [
      {
        "text": "Implement NGS-first reflex testing protocol for metastatic CRC",
        "icon": "document"
      },
      {
        "text": "Create liquid biopsy pathway for tissue-limited cases",
        "icon": "flask"
      },
      {
        "text": "Develop HER2 testing implementation strategy",
        "icon": "cog"
      },
      {
        "text": "Establish molecular tumor board for complex cases",
        "icon": "users"
      }
    ]
  },
  "weighted_score": 94,
  "action_steps": [
    {
      "text": "Implement universal NGS panel for all metastatic CRC",
      "icon": "document"
    },
    {
      "text": "Create CRC-specific tissue collection protocol",
      "icon": "clipboard"
    },
    {
      "text": "Develop HER2 testing protocol for KRAS wild-type cases",
      "icon": "flask"
    },
    {
      "text": "Establish testing method tracking dashboard",
      "icon": "chart"
    }
  ],
  "suggestions": [
    {
      "text": "Evaluate tissue acquisition/adequacy challenges",
      "icon": "search"
    },
    {
      "text": "Consider combined DNA/RNA-based NGS approach",
      "icon": "lightbulb"
    }
  ],
  "drilldowns": [
    {
      "label": "By Provider",
      "cohort": "CRC Testing by Provider",
      "jsonFile": "crc-biomarker-by-provider.json",
      "drilldownLevel": 3
    },
    {
      "label": "All CRC Biomarkers",
      "cohort": "CRC Biomarker Testing",
      "jsonFile": "crc-biomarker.json",
      "drilldownLevel": 2
    },
    {
      "label": "All Methods",
      "cohort": "Biomarker Testing by Method",
      "jsonFile": "biomarker-compliance-by-method.json",
      "drilldownLevel": 1
    },
    {
      "label": "Overall Compliance",
      "cohort": "Biomarker Testing Compliance",
      "jsonFile": "biomarker-compliance.json",
      "drilldownLevel": 0
    }
  ]
} 